Highlights

  • Telix Pharmaceuticals (ASX:TLX) reported Q2'2026 Revenue of US$247 million, up 21% year-on-year.
  • The company expects FY26 revenue and other income to exceed US$1 billion.
  • US prostate cancer imaging products remain the primary commercial contributor.
  • Regulatory progress across imaging and therapeutic programs remains central to future growth.

Telix Pharmaceuticals (ASX:TLX) has continued its commercial expansion in radiopharmaceuticals, reporting record quarterly revenue and outlining a pathway towards more than US$1 billion in full-year revenue and other income.

The company’s imaging Business remains the primary revenue driver, while regulatory progress across therapeutic and diagnostic programs provides additional development opportunities.

However, future growth will depend on maintaining commercial performance while advancing a broader pipeline of clinical and regulatory programs.

What Happened?

On 20 July 2026, Telix Pharmaceuticals released its Q2'2026 update, reporting group revenue of US$247 million.

The result represented growth of approximately 7% compared with Q1'2026 and 21% year-on-year.

The Precision Medicine division generated US$202 million in revenue, while the Therapeutics, Manufacturing and Sustainability segment contributed US$45 million.

The company’s US prostate cancer imaging portfolio remained the main contributor, supported by Illuccix and Gozellix.

Telix also reiterated expectations that FY26 revenue would reach the upper end of its US$950 million to US$970 million guidance range.

Why It Matters

Telix has developed a commercial radiopharmaceutical business with significant US exposure, generating product revenue rather than relying primarily on licensing income.

The company’s potential milestone of exceeding US$1 billion in annual revenue and other income reflects the scale achieved by its imaging franchise.

The transition between products is also important. Gozellix is being adopted alongside Illuccix, supporting continued growth in the US PSMA imaging market.

The company is also using revenue from imaging products to fund expansion into therapeutic radiopharmaceuticals, where it sees additional long-term opportunities.

The Numbers

All figures below are in US dollars unless stated otherwise.

Q2'2026 group revenue was US$247 million.

Revenue by segment included:

  • Precision Medicine: US$202 million, up approximately 30% year-on-year.
  • Therapeutics, Manufacturing and Sustainability: US$45 million, down approximately 6% year-on-year.

US dose volumes increased 7% during the quarter, supported by Gozellix Demand and continued imaging product adoption.

Telix expects FY26 product revenue of US$950 million to US$970 million.

The company also received US$40 million in non-refundable other income from the Regeneron collaboration.

Combined revenue and other income is therefore expected to exceed US$1 billion.

Telix increased its Research and Development expenditure guidance to US$230 million to US$270 million to support pipeline acceleration.

The Bigger Picture

Telix’s strategy is built around using its imaging business to support development of therapeutic radiopharmaceuticals.

The company is advancing multiple programs across cancer imaging and targeted treatment.

Its kidney cancer imaging candidate TLX250-Px (Zircaix) is progressing towards a Biologics licence application resubmission.

The brain cancer imaging product TLX101-Px (Pixclara) has had its resubmitted new drug application accepted by the FDA, with a target decision date of 11 September 2026.

The lead therapeutic program, TLX591-Tx, is being evaluated in the ProstACT Global Phase 3 trial for metastatic prostate cancer.

Telix has also expanded manufacturing capability and radiopharmacy infrastructure through its RLS operations.

The Bull Case

The positive case for Telix Pharmaceuticals (ASX:TLX) is based on its established imaging revenue base and expanding radiopharmaceutical pipeline.

The company has demonstrated commercial adoption of PSMA imaging products in the United States.

Additional regulatory approvals across imaging programs could broaden revenue sources.

The therapeutic pipeline provides longer-term opportunities by applying Telix’s targeting technology beyond diagnostics.

The Regeneron collaboration and manufacturing expansion also provide additional strategic support for future development.

Risks Investors Should Understand

Telix Pharmaceuticals (ASX:TLX)’s business faces risks including market concentration, regulatory uncertainty, clinical trial outcomes and increased Investment requirements.

The company’s revenue remains heavily linked to US prostate cancer imaging, creating exposure to competition, pricing pressure and reimbursement changes.

Therapeutic programs remain subject to clinical trial outcomes and regulatory approval.

Pending regulatory decisions for Pixclara and Zircaix may not result in approval.

Higher research and development spending and increased Debt following Convertible Bond issuance may also affect financial flexibility.

Currency movements may influence reported results when US-dollar Earnings are translated into Australian dollars.

What Comes Next?

The next major milestones include the FDA decision on Pixclara expected on 11 September 2026 and further progress on the Zircaix regulatory pathway.

Investors will also monitor enrolment and development progress in the ProstACT Global Phase 3 trial.

The FY26 results will provide further detail on revenue delivery, margins and cash generation as Telix continues investing in its pipeline.

Conclusion

Telix Pharmaceuticals (ASX:TLX) has continued its commercial expansion with US$247 million in Q2'2026 revenue and a pathway towards exceeding US$1 billion in annual revenue and other income.

The imaging business continues to provide the commercial foundation, while regulatory and therapeutic programs create additional future opportunities.

However, the company’s next phase depends on maintaining imaging growth, progressing clinical programs and managing the financial requirements of a broader radiopharmaceutical pipeline.